CZ VACCINES

czvaccines.com

CZ Vaccines, before Known as CZ Veterinaria, is a worldwide leader in the application of advances in biotechnology to vaccine production and one of the foremost biotechnology companies in the European Union. CZ Vaccines has a strong presence across 60 countries. CZ Vaccines is a biopharmaceutical company that is dedicated exclusively to the development and manufacture of veterinary products and medicines. State-of-the-art technology, modern production systems and high-performance manufacturing plants that meet stringent quality standards are the foundation that guarantees the production of cutting edge products. CZ Vaccines has its own products that are distributed through third parties. In addition, it contract manufactures a comprehensive range of pharmaceutical and biological products for large multinational companies and governments around the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TSCAN AND NOVARTIS PARTNER TO DEVELOP CANCER THERAPIES

Pharmaceutical Technology | April 16, 2020

news image

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer. The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments. As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets. Furthermore, Novartis wil...

Read More

PHARMACY MARKET

TARSIER PHARMA RAISES CAPITAL TO EXECUTE PHASE-3 CLINICAL TRIAL

Tarsier Pharma | August 28, 2021

news image

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regu...

Read More

RESEARCH

EXSCIENTIA AND BRISTOL MYERS SQUIBB ENTER INTO A MULTI-TARGET, AI-DRIVEN DRUG DISCOVERY PARTNERSHIP

Exscientia, Bristol Myers Squibb | May 20, 2021

news image

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...

Read More

ULTRAGENYX PHARMACEUTICAL INC ANNOUNCES U.S. FDA APPROVAL OF DOJOLVI™ FOR THE TREATMENT OF LONG-CHAIN FATTY ACID OXIDATION DISORDERS

Ultragenyx | July 03, 2020

news image

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Dojolvi™ (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD are a group of rare, lifelong and life...

Read More
news image

TSCAN AND NOVARTIS PARTNER TO DEVELOP CANCER THERAPIES

Pharmaceutical Technology | April 16, 2020

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer. The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments. As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets. Furthermore, Novartis wil...

Read More
news image

PHARMACY MARKET

TARSIER PHARMA RAISES CAPITAL TO EXECUTE PHASE-3 CLINICAL TRIAL

Tarsier Pharma | August 28, 2021

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regu...

Read More
news image

RESEARCH

EXSCIENTIA AND BRISTOL MYERS SQUIBB ENTER INTO A MULTI-TARGET, AI-DRIVEN DRUG DISCOVERY PARTNERSHIP

Exscientia, Bristol Myers Squibb | May 20, 2021

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...

Read More
news image

ULTRAGENYX PHARMACEUTICAL INC ANNOUNCES U.S. FDA APPROVAL OF DOJOLVI™ FOR THE TREATMENT OF LONG-CHAIN FATTY ACID OXIDATION DISORDERS

Ultragenyx | July 03, 2020

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Dojolvi™ (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD are a group of rare, lifelong and life...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us